Aug 17, 2026 · 6 min
Mining gains meet drug-trial surprises across European markets
Fresnillo AstraZeneca Climbs, Argenx Surges
The episode shows how commodity strength, clinical setbacks, and late-stage drug success can move shares in sharply different directions.
- 1Copper and gold strength lifts British mining stocks, including Fresnillo, as competition for supply intensifies.
- 2AstraZeneca gains despite stopping a lung-cancer trial that failed to outperform existing therapies.
- 3Argenx surges on late-stage immune-disease results that could support US approval and reduce reliance on immunosuppressants.
Don't miss
Argenx shares surge after positive late-stage results for an immune-disease treatment, potentially opening a path toward US approval.
The brief
British mining stocks rise as copper approaches record levels and gold remains supportive, putting Fresnillo and other precious-metals producers in focus.
AstraZeneca shares climb despite a setback in oncology: the company halted a lung-cancer drug trial after it failed to beat existing therapies.
Argenx delivers the episode’s sharpest move, surging after positive late-stage results for an immune-disease treatment that could support US approval.
The report ends by previewing a broader discussion with Jacob Greaves on AI, urban development, and Dubai’s long-term response to rapid population growth.
Together, the market moves show how investors can reward commodity exposure and clinical progress while treating a trial failure as a contained setback.
What was said on this episode
7 statements · 6 positive · 1 negative
Copper prices are approaching record highs.
“Copper is rising towards record highs.”
Listen at 0:59
Gold prices are rising.
“And gold is also rising.”
Listen at 1:10
Mining stocks are performing strongly overall.
“So overall, strong performance for miners.”
Listen at 1:24
The failed trial is a slight setback for AstraZeneca.
“So, a slight setback there.”
Listen at 2:02
Argenx shares rose as much as 10%.
“shares up as much as 10%.”
Listen at 2:45
Argenx's drug helps patients with an immune-system disease.
“this helps patients with an immune system disease.”
Listen at 2:53
AI will compress processes in smart-city systems.
“AI will allow in the smart city space to compress a lot of things.”
Listen at 4:00
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.